NEW YORK, NY / ACCESS Newswire / February 13, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a ...

NEW YORK, NY / ACCESS Newswire / February 12, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a ...

Shares of GSK PLC GSK advanced 1.56% to £14.66 Monday, on what proved to be an all-around positive trading session for the stock market, with the FTSE 100 Index UKX rising 0.77% to 8,767.80. GSK PLC ...

Biopharmaceutical company GSK is growing its Massachusetts work force, announcing plans to move its vaccines research and development and infectious disease teams from suburban Maryland to ...

CEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over £31 billion, with specialty medicines driving performance. Core operating profit grew 13%, supporting a ...

In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other stocks. The stock market extended its winning streak on Wednesday, closing firmer as investors ...

NYSE GSK opened at $34.91 on Tuesday. GSK plc has a 52 week low of $31.72 and a 52 week high of $45.92. The firm has a market capitalization of $72.34 billion, a P/E ratio of 22.67, a PEG ratio of ...

Feb 5 (Reuters) - UK's FTSE 100 firmed on Wednesday after two straight days of losses, buoyed by gains in shares of heavyweight GSK and gold miners, while investors turned their focus to the Bank ...

GSK (GSK), a large British drug maker, is rallying 8% after reporting higher-than-expected fourth-quarter earnings per share and raising its long-term revenue guidance. Last quarter, its operating ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. GSK does not need a miracle cure — just some rest and rehabilitation. Investors, though, seem unwilling ...

Harvey Jones has something to celebrate after a positive set of results boosted the GSK share price after a disappointing run. Is there scope for more growth? The content of this article is ...

GSK today increased its 2031 sales outlook to more than £40 billion, up from £38 billion amid stronger progress in its late-stage drugs pipeline. Total 2024 sales in GSK’s annual results published ...